By: Anabelle Faivre
More than five years after first filing suit in June 2020, a group of states is pursuing sweeping antitrust claims against thirty-six pharmaceutical defendants.[1] The multistate litigation continues to gain traction, as a federal judge in Connecticut recently rejected most of the pharmaceutical companies’ efforts to dismiss key claims, concluding that genuine material fact disputes warrant a trial.[2]
The litigation—brought by Connecticut and a coalition of nearly all states and territories—alleges that manufacturers conspired to artificially inflate prices and restrict competition in markets for dozens of generic drugs, including a third complaint focusing on eighty topical medications accounting for billions in U.S. sales.[3] The states allege coordinated price-fixing conspiracies spanning eighty generic drugs and seek to hold each company jointly and severally liable for an industry-wide scheme—regardless of whether a particular manufacturer sold or produced a specific drug at issue.[4]
In a December 2025 ruling, the court denied the defendants’ motion for summary judgment, noting that evidence such as information sharing among competitors could support the states’ conspiracy claims.[5] States and cooperating plaintiffs have already secured settlements from some companies and executives, and potential compensation may be available for consumers who purchased affected drugs between 2009 and 2019.[6]
The case underscores the critical role of antitrust enforcement in healthcare markets, particularly for ensuring the affordability and accessibility of essential medications.[7] When generic drug manufacturers conspire to fix prices or allocate markets, patients, insurers, and government programs such as Medicare and Medicaid may pay inflated costs for drugs that should otherwise be competitively priced.[8] Successful enforcement of these antitrust claims could restore market competition, potentially lowering costs for consumers and improving access to critical medications.[9] Additionally, the Connecticut court’s decision signals to regulators and healthcare stakeholders that coordinated pricing schemes in healthcare are taken seriously, reinforcing the principle that the law protects patients from anticompetitive practices.[10]
For patients relying on generic medications, alleged price-fixing could have meant paying significantly more for essential treatments, putting both families, insurers, and government payers under financial strain; research on “generic-drug cartel” behavior shows that prices for some generic drugs rose forty to fifty percent when collusion occurred.[11] Research on U.S. prescription drug markets shows that when there are few or no generic competitors for off-patent medicines, prices can rise sharply even after patent expiry.[12] These higher costs can reduce patient access to affordable drugs, underscoring the importance of strong generic competition and low generic prices for protecting public health and keeping medicines affordable.[13] Cost-related barriers to medication are significant, with millions of Americans reporting that they skip or delay prescriptions because of high drug prices—often resulting in poorer health outcomes.[14]
For pharmaceutical companies and executives, the court’s decision in the Connecticut litigation illustrates the significant corporate and personal liability risks associated with anticompetitive behavior.[15] By finding that the states have presented sufficient evidence of coordinated behavior to survive dismissal, the court signaled a willingness to scrutinize parallel pricing and inter-company communications more closely.[16] If adopted more broadly, this approach could expand potential exposure for manufacturers nationwide, though variations in state antitrust statutes and enforcement priorities may continue to make some jurisdictions comparatively more favorable business environments than others.[17] Companies may face hundreds of millions or even billions in damages, along with reputational harm that can affect investor confidence and market positioning.[18] The litigation also highlights the importance of robust compliance programs to ensure adherence to federal and state antitrust laws.[19] Past enforcement actions involving companies such as Teva Pharmaceuticals demonstrate that price-fixing allegations can generate substantial legal costs and operational disruption.[20]
From a business perspective, the case underscores how antitrust scrutiny can influence real-world corporate strategy.[21] Executives must be careful in communications and business planning to avoid the appearance of collusion, as information sharing or coordinated pricing could be construed as unlawful.[22] The heightened enforcement climate may also affect mergers, partnerships, and pricing strategies—especially in a sector where consolidation has historically been used to stabilize margins in competitive generic markets.[23] Companies evaluating acquisitions or supply agreements may not face increased diligence burdens, while some firms have already reassessed pricing practices or internal controls in response to litigation risk tied to similar investigations.[24] In this way, the Connecticut decision does not operate solely as a legal development; it will shape how pharmaceutical companies structure deals, manage competitor relationships, and balance profitability with compliance in an increasingly enforcement-focused environment.[25]
[1] Hailey Konnath, States’ Generic Drugs Antitrust Case Headed Toward Trial, Law 360 (Feb. 13, 2026, at 22:42 ET), https://www.law360.com/health/articles/2441778/states-generic-drugs-antitrust-case-headed-toward-trial [https://perma.cc/B483-S3KF].
[2] See id.
[3] Press Release, Off. of the Att’y Gen., Conn., Attorney General Tong Announces Development in Generic Drug Price-Fixing Case (Dec. 4, 2025), https://portal.ct.gov/ag/press-releases/2025-press-releases/attorney-general-tong-announces-development-in-generic-drug-price-fixing-case [https://perma.cc/Y5PA-FG9N] [hereinafter Press Release].
[4] See id.
[5] See id.; Connecticut v. Sandoz, Inc., No. 3:20-CV-00802-MPS, 2025 WL 3470502, at *1 (D. Conn. Dec. 3, 2025) (denying motion for summary judgment).
[6] See id.
[7] See Konnath, supra note 1.
[8] See Press Release, supra note 3.
[9] See generally Konnath, supra note 1 (reporting allegations that generic drug manufacturers colluded to limit competition and significantly raise prices of dozens of generic products).
[10] See Press Release, supra note 3.
[11] Amanda Starc & Thomas G. Wollman, Consumers Pay When Generic Drug Companies Collude. Here’s a Way to Stop Them, KellogInsight (June 1, 2022), https://insight.kellogg.northwestern.edu/article/consumers-pay-when-generic-drug-companies-collude [https://perma.cc/D6FA-FGMX].
[12] Ravi Gupta, Nilay D. Shah & Joseph S. Ross, Generic Drugs in the United States: Policies to Address Pricing and Competition, 105 Clinical Pharmacology Therapeutics 329, 330 (2019).
[13] See id.
[14] Sherri Gordon, CDC Reports: 9 Million Americans Not Taking Medications as Prescribed Due to Cost, Health (May 18, 2024), https://www.health.com/drug-costs-united-states-cdc-7509659 [https://perma.cc/SX94-VVSN].
[15] See Konnath, supra note 1.
[16] See Press Release, supra note 3 (Judge Shea found that “[t]he States . . . marshaled a substantial bulk of evidence to support [their] allegations,” and that “a reasonable juror could infer that sharing information with competitors, providing assurances that a generic drug maker would follow price increases, and refraining from poaching customers were widespread practices in the markets for the Drugs at Issue”).
[17] See Dana Cook-Milligan, Antitrust 101: State Antitrust Enforcement, Winston & Strawn LLP (July 17, 2025), https://www.winston.com/en/blogs-and-podcasts/competition-corner/antitrust-101-state-antitrust-enforcement [https://perma.cc/CME8-JEGA].
[18] See Press Release, supra note 3.
[19] See id.
[20] See Jaclyn Jaeger, Teva to Pay Record $225M for Role in Antitrust Cartel; Glenmark to Pay $30M, Compliance Chief 360° (Aug. 22, 2023), https://compliancechief360.com/teva-to-pay-record-225m-for-role-in-antitrust-cartel-glenmark-to-pay-30m/ [https://perma.cc/38TG-MZ5W] (noting Teva was required to pay a $225 million criminal penalty in addition to donating $50 million worth of its products to humanitarian organizations after being found guilty of price-fixing).
[21] Grace Nakato et al., The Impact of Antitrust Laws on Corporate Growth Strategies: How Regulations are Shaping Business Competition and Market Dominance, 6 J. of Advanced Rsch. and Transformative Knowledge 153, 154 (2026) (providing business decisions such as market entry, pricing policies, and investment allocations as examples that can be influenced by antitrust regulations).
[22] See Press Release, supra note 3.
[23] See generally Nakato et al., supra note 21 (explaining that regulations may temporarily slow growth, but companies adapt, driving an overall upward trajectory as strategies evolve in response to changing rules.).
[24] See id. at 158 (highlighting that stricter antitrust enforcement can result in “reduced market concentration, it also increased compliance costs for firms, leading to pricing adjustments and shifts in digital marketing strategies”).
[25] See generally id. at 156 (“Antitrust laws play a crucial role in regulating corporate growth strategies by shaping market competition and limiting monopolistic practices.”).
